Significant delay in the progression to dialysis/ESIRD for AA amyloidosis patients treated with eprodisate (NC-503): 3 years of follow-up

dc.contributor.author	Merlini, G.
dc.contributor.author	Lachmann, H.
dc.contributor.author	Puechal, V
dc.contributor.author	Dember, L.
dc.contributor.author	Hauck, W.
dc.contributor.author	Hatemi, G.
dc.contributor.author	Ozdogan, H.
dc.contributor.author	Hazenberg, B.
dc.contributor.author	Gul, A.
dc.date.accessioned	2021-03-06T13:16:33Z
dc.date.available	2021-03-06T13:16:33Z
dc.identifier.citation	Hatemi G., Ozdogan H., Hazenberg B., Gul A., Puechal V., Merlini G., Lachmann H., Hauck W., Dember L., "Significant delay in the progression to dialysis/ESIRD for AA amyloidosis patients treated with eprodisate (NC-503): 3 years of follow-up", ZEITSCHRIFT FUR RHEUMATOLOGIE, cilt.66, ss.48, 2007
dc.identifier.issn	0340-1855
dc.identifier.other	vv_1032021
dc.identifier.other	av_f7e11a19-dd68-4b48-944a-94df459113e5
dc.identifier.uri	http://hdl.handle.net/20.500.12627/162348
dc.language.iso	eng
dc.subject	İmmünoloji ve Romatoloji
dc.subject	ROMATOLOJİ
dc.subject	Klinik Tıp
dc.subject	Klinik Tıp (MED)
dc.subject	Tıp
dc.subject	Sağlık Bilimleri
dc.subject	Dahili Tıp Bilimleri
dc.subject	İç Hastalıkları
dc.title	Significant delay in the progression to dialysis/ESIRD for AA amyloidosis patients treated with eprodisate (NC-503): 3 years of follow-up
dc.type	Makale
dc.relation.journal	ZEITSCHRIFT FUR RHEUMATOLOGIE
dc.contributor.department	, ,
dc.identifier.volume	66
dc.identifier.startpage	48
dc.identifier.endpage	48
dc.contributor.firstauthorID	184542

Files in this item

Files	Size	Format	View
There are no files associated with this item.